OrthoPediatrics (NASDAQ: KIDS) furnishes investor presentation for analyst meetings

Rhea-AI Filing Summary

OrthoPediatrics Corp. filed a current report describing upcoming presentations by its executive officers to investors and analysts. The company has prepared an investor presentation that is included as Exhibit 99.1 and may be used, in whole or in part, during these meetings. The investor presentation and related information are being furnished under a Regulation FD disclosure item and are not considered filed for liability purposes under the Securities Exchange Act of 1934 or automatically incorporated into other securities law filings.

0001425450FALSE00014254502023-01-092023-01-09

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

______________________

Date of Report (Date of earliest event reported): January 12, 2026

OrthoPediatrics Corp.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

001-38242			26-1761833
(Commission File Number)			(I.R.S. Employer Identification Number)

2850 Frontier Drive Warsaw, Indiana			46582
(Address of principal executive offices)			(Zip Code)

Registrant’s telephone number, including area code: (574) 268-6379

Not Applicable

(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.00025 par value per share

KIDS

Nasdaq Global Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 under the Securities Act (17 CFR 230.405) or Rule 12b-2 under the Exchange Act (17 CFR 240.12b-2).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ¨

Item 7.01. Regulation FD Disclosure.

The executive officers of OrthoPediatrics Corp. have several upcoming presentations to representatives of investors and analysts. The officers intend to use the material filed as Exhibit 99.1 herewith, in whole or in part, as part of those presentations.

The information in this Item 7.01, including the information incorporated by reference herein from Exhibit 99.1, is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d)			Exhibits
			Exhibit No.			Description
			99.1			Orthopediatrics Corp. Investor Presentation dated January 2026
			104			Cover Page Interactive Data File (embedded within the Inline XBRL document).

* * * * * *

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			OrthoPediatrics Corp.
Date:   January 12, 2026			By:			/s/ Daniel J. Gerritzen
						Daniel J. Gerritzen, General Counsel and Secretary

- 2 -

FAQ

What did OrthoPediatrics Corp. (KIDS) disclose in this 8-K?

OrthoPediatrics Corp. disclosed that its executive officers will give presentations to investors and analysts and may use an investor presentation furnished as Exhibit 99.1.

What is Exhibit 99.1 in OrthoPediatrics Corp. (KIDS) latest filing?

Exhibit 99.1 is an OrthoPediatrics Corp. investor presentation that the company’s executive officers intend to use during upcoming meetings with investors and analysts.

Is the OrthoPediatrics (KIDS) investor presentation considered filed with the SEC?

No. The investor presentation in Exhibit 99.1 is furnished under a Regulation FD disclosure item and is expressly stated not to be deemed filed for purposes of Section 18 of the Exchange Act.

Will the OrthoPediatrics (KIDS) investor materials be incorporated into other SEC filings?

The materials furnished under this Regulation FD disclosure are not incorporated by reference into Securities Act or Exchange Act filings unless a future filing specifically incorporates them by reference.

Which SEC item does OrthoPediatrics Corp. (KIDS) use for this disclosure?

The company uses Item 7.01, Regulation FD Disclosure, to furnish the investor presentation information to the market.

Who signed the OrthoPediatrics Corp. (KIDS) 8-K report?

The report was signed on behalf of OrthoPediatrics Corp. by Daniel J. Gerritzen, who is the company’s General Counsel and Secretary.